MRC Technology and Shandong International Biotechnology Park (BIOasis) have signed a partnership agreement for the development of a new Alzheimer’s drug.

Signed by Fu Fenghua, General Manager of BIOasis and Michael Dalrymple, Director of Business Development at MRC Technology, the development of a new drug for Alzheimer’s could be significant to over 35 million people currently affected by the disease.

Financial terms have not been disclosed.